Indication
Factor XI Deficiency
1 clinical trial
1 product
Clinical trial
Single-center, Randomized, Double-blind, Placebo-controlled, Sequential Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAD of FXI-GalNAc-siRNA When Administered Subcutaneously to Healthy Subjects.Status: Recruiting, Estimated PCD: 2024-05-01
Product
FXI-GalNAc-siRNA